Abstract
There is increasing evidence that acute bacterial and viral infection represent trigger factors that temporarily elevate the risk of ischemic stroke. During and after influenza epidemics vascular death rates and hospitalizations for stroke are increased. Influenza vaccination is an effective measure to reduce hospitalization and mortality in the elderly and work incapacity in adults of working age. Results of several observational studies support the hypothesis that influenza vaccination is associated with reduced odds of stroke. As randomized studies are lacking, a causal role of influenza vaccination in stroke prevention is not proven, however. According to current guidelines in many countries, that recommend the vaccination in all patients with chronic vascular disease, all patients with a history of stroke or TIA should receive an influenza vaccination annually. Furthermore, patients with diabetes mellitus or with a combination of risk factors that increase stroke risk should obtain the vaccination. In addition, there is evidence from observational data that the neuraminidase inhibitor oseltamivir reduces the risk of stroke within 6 months after influenza infection.
Keywords: Acute infections, influenza, stroke, risk factor, cerebral ischemia, vascular disease, vaccination, antivirals
Infectious Disorders - Drug Targets
Title: Influenza and Stroke Risk: A Key Target Not to be Missed?
Volume: 10 Issue: 2
Author(s): Christian Urbanek, Frederick Palm and Armin J. Grau
Affiliation:
Keywords: Acute infections, influenza, stroke, risk factor, cerebral ischemia, vascular disease, vaccination, antivirals
Abstract: There is increasing evidence that acute bacterial and viral infection represent trigger factors that temporarily elevate the risk of ischemic stroke. During and after influenza epidemics vascular death rates and hospitalizations for stroke are increased. Influenza vaccination is an effective measure to reduce hospitalization and mortality in the elderly and work incapacity in adults of working age. Results of several observational studies support the hypothesis that influenza vaccination is associated with reduced odds of stroke. As randomized studies are lacking, a causal role of influenza vaccination in stroke prevention is not proven, however. According to current guidelines in many countries, that recommend the vaccination in all patients with chronic vascular disease, all patients with a history of stroke or TIA should receive an influenza vaccination annually. Furthermore, patients with diabetes mellitus or with a combination of risk factors that increase stroke risk should obtain the vaccination. In addition, there is evidence from observational data that the neuraminidase inhibitor oseltamivir reduces the risk of stroke within 6 months after influenza infection.
Export Options
About this article
Cite this article as:
Urbanek Christian, Palm Frederick and Grau J. Armin, Influenza and Stroke Risk: A Key Target Not to be Missed?, Infectious Disorders - Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/187152610790963474
DOI https://dx.doi.org/10.2174/187152610790963474 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Sitagliptin on Non-diabetic Covid-19 Patients
Current Molecular Pharmacology Angiotensin II Regulates Vascular and Endothelial Dysfunction: Recent Topics of Angiotensin II Type-1 Receptor Signaling in the Vasculature
Current Vascular Pharmacology Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot Topic: Carbon Monoxide - A Toxic Gas on the Edge to Clinical Application (Guest Editor: Rene Schmidt)]
Current Pharmaceutical Biotechnology Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Current Medicinal Chemistry Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population
Current Alzheimer Research Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology A Copeptin as a Predictor Marker for Insulin Resistance Among Women with Polycystic Ovary Syndrome
Current Women`s Health Reviews Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology The Role of Niacin in Lipid-lowering Treatment: Are we Aiming Too High?
Current Pharmaceutical Design Medical Treatment of Chronic Venous Insufficiency
Vascular Disease Prevention (Discontinued) Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Current Pharmaceutical Design Altered Steroid Metabolism and Insulin Signaling in PCOS Endometria: Impact in Tissue Function
Current Pharmaceutical Design Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry